Xilio Therapeutics (XLO) logo

Xilio Therapeutics (XLO) stock

Worth $60.3MShares as of Nov 6

$8.53
-5.22%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score XLO. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

Next2H 2026“…metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors in the second half of 2026…”Trial start · SEC filing · Aug 12
Cash$122M, about 8 quarters (2 years) at the last year's spendingOn Sep 30 · the company says “into the first quarter of 2028”

Follow XLO's news. Pro members can get an alert when Xilio Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when XLO files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$122M, about 8 quarters (2 years) at the last year's spendingOn Sep 30 · the company says “into the first quarter of 2028”

What's next for XLO, and how long its cash lasts

Next step the company has named

2H 2026“…expects to initiate dosing in the Phase 1 portion of the trial in patients with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors in the second half of 2026.”Trial start · SEC filing · Aug 12

What it means: when a trial begins, or reaches the stage the company named.

For Pro members: 4 more milestones and 42 filings.

Cash runway Sep 30 balance sheet

About 8 quarters

$122M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into the first quarter of 2028” (8-K, Nov 10).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed May 12, 2026)
  • At-the-market share sales program (S-3, filed May 12, 2026)

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

Director James Samuel Shannon bought 5,000 shares on Mar 26. 2 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Rene Russo’s 13 filings and quotes.

Get an alert when XLO files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

XLO's latest filings

27 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why XLO isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. XLO trades about 17,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See every stock ranked

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

The price on this page is delayed at least 15 minutes.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.